measured GFRs as high as 180 mL/min and used measured GFRs up to 136 mL/min to calculate carboplatin doses. 8 The US Food and Drug Administration (FDA) recommends that CrCl greater than 125 mL/min, as estimated by the Cockcroft-Gault method, should not be used to calculate carboplatin doses in the Calvert equation. 18 
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing carboplatin and paclitaxel. A. Nab-paclitaxel 1. Use nab-paclitaxel powder for injection. 2. Reconstitute the lyophilized powder with 0.9% sodium chloride injection (NS) to a concentration of 5 mg/mL. a. To prevent foaming, avoid rapid injection of fl uid or vigorous shaking of the vial. b. Allow the vial to sit for a minimum of 5 minutes to ensure proper wetting of the lyophilized cake. c. Gently swirl and/or invert the vial slowly until the particles are evenly dispersed. 3. Dispense in an empty, sterile intravenous (IV) bag. B. Carboplatin 1. Use carboplatin injection 10 mg/mL, or powder for reconstitution. 2. Reconstitute the powder to a concentration of 10 mg/mL with sterile water for injection (SWFI), 5% dextrose in water (D5W), or 0.9% sodium chloride (NS).
3. Dilute with 100 to 1,000 mL of D5W or NS. 4. Carboplatin is less stable in saline solutions, with up to 5% degradation within 24 hours. 19 5. If the drug is prepared in a saline diluent, the solution should be used within 8 hours.
DRUG ADMINISTRATION
A. Nab-paclitaxel 1. The manufacturer recommends the drug be given as a 30-to 40-minute IV infusion. 2. Infusion over 30 minutes has been associated with grade 3 or 4 peripheral neuropathy. Administering the drug over 2 hours has been shown to decrease the average severity of grade 2 or greater peripheral neuropathy without affecting survival. 20 B. Carboplatin: Administer by IV infusion over 30 to 60 minutes.
SUPPORTIVE CARE A. Acute and Delayed Emesis Prophylaxis:
The nab-PC regimen is predicted to cause vomiting in 30% to 90% of patients on day 1 and in 10% to 30% of patients on day 8 and day 15. [21] [22] [23] The studies reviewed reported nausea in 24% to 68% 1-3 of patients, grade 3 to 4 nausea in less than 1% to 11% 1-3,5,6 of patients, and vomiting in 33% of patients. 1 Appropriate acute emesis prophylaxis includes a serotonin antagonist and a corticosteroid plus or minus a neurokinin antagonist in selected patients. 21-23 One of the following regimens is suggested: Cycle repeats every 21 days.
Variations: 1. Nab-paclitaxel 225 mg/m 2 and carboplatin AUC 6 given on day 1 of a 21-day cycle. 4 2. Nab-paclitaxel 260 mg/m 2 and carboplatin AUC 6 given on day 1 of a 21-day cycle. 4 3. Nab-paclitaxel 300 mg/m 2 and carboplatin AUC 6 given on day 1 of a 21-day cycle. 4 4. Nab-paclitaxel 340 mg/m 2 and carboplatin AUC 6 given on day 1 of a 21-day cycle. 4 5. Nab-paclitaxel 140 mg/m 2 on day 1 and 8, and carboplatin AUC 6 on day 1 of a 21-day cycle. 4 6. Nab-paclitaxel 100 mg/m 2 on day 1, 8, and 15, and carboplatin AUC 6 on day 1 of a 21-day cycle. 4 7. Nab-paclitaxel 125 mg/m 2 on day 1, 8, and 15, and carboplatin AUC 6 on day 1 of a 21-day cycle. 4
Note: AUC = area under the time vs concentration curve; IV = intravenous. 21, 22 or metoclopramide 10 to 40 mg PO 21,23 or prochlorperazine 10 mg PO. 21,23 A single dose of an oral serotonin antagonist may also be considered. 21, 23 The antiemetic therapy should continue for at least 2 days after day 1. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid or a steroid and dopamine antagonist combination most appropriate for follow-up therapy. 24 One of the following regimens is suggested: 
C. Hematopoietic Growth Factors:
Accepted practice guidelines and pharmaco economic analysis suggest that antineoplastic regimens have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSF) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSF should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSF is not recommended. 25 In the trials reviewed, neutropenia was reported in 83% to 94% 1-3 of patients and grade 3 to 4 neutropenia in 45% to 69% 1-6 of patients. Febrile neutropenia was reported in 3% to 11%. 1, 3 Prophylactic use of CSF is not r ecommended with this regimen. CSF should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of nab-PC.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Constitutional: Fatigue (all grades) 33% to 74%, 1-3 (grade 3 or 4) 3% to 6%. 2,3,5,6 B. Dermatologic: Alopecia (all grades) 49% to 100%, 1-3 (grade 3 or 4) 1% 3, 6 
